|
Status |
Public on Feb 13, 2019 |
Title |
Type I Interferon Delivery by iPSC-Derived Myeloid Cells Elicits Antitumor Immunity via XCR1+ Dendritic Cells |
Organism |
Mus musculus |
Experiment type |
Expression profiling by high throughput sequencing
|
Summary |
This SuperSeries is composed of the SubSeries listed below.
|
|
|
Overall design |
Refer to individual Series
|
|
|
Citation missing |
Has this study been published? Please login to update or notify GEO. |
|
Submission date |
Feb 08, 2019 |
Last update date |
Mar 21, 2019 |
Contact name |
Ranmaru Shimoda |
E-mail(s) |
shimoda@rhelixa.com
|
Phone |
+818043368250
|
Organization name |
Rhelixa, Inc.
|
Street address |
3F Yayoi Bldg., 3-7-4 Iwamotocho
|
City |
Chiyoda |
State/province |
Tokyo |
ZIP/Postal code |
101-0032 |
Country |
Japan |
|
|
Platforms (2) |
GPL16417 |
Illumina MiSeq (Mus musculus) |
GPL17021 |
Illumina HiSeq 2500 (Mus musculus) |
|
Samples (32)
|
|
This SuperSeries is composed of the following SubSeries:
|
GSE126277 |
IFN-α-producing proliferating myeloid cells reveal type I IFN-stimulating gene signature |
GSE126278 |
Characterization of tumor-infiltrating T cells by TCR-β repertoire analyses |
GSE126279 |
Local administration of IFN-α-iPSC-pMCs alters gene expression profiles in tumor microenvironment. |
GSE126280 |
Allele imbalance in Reps1 and Adpgk |
|
Relations |
BioProject |
PRJNA521782 |